×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RARE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/6
04:00 pm
rare
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE
Low
Report
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE
4/6
10:51 am
rare
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
Low
Report
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
4/6
09:26 am
rare
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Low
Report
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
4/6
09:20 am
rare
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
4/6
03:44 am
rare
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
4/6
02:24 am
rare
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
Low
Report
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
4/5
06:37 pm
rare
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE
Low
Report
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE
4/5
12:00 pm
rare
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
04:01 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-12.7%
ultragenyx pharmaceutical inc.
11/4/2025
04:05 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-1.8%
ultragenyx pharmaceutical inc.
8/5/2025
04:07 pm
RARE
ultragenyx pharmaceutical inc.
BEAT
Report
-4.9%
ultragenyx pharmaceutical inc.
5/6/2025
04:01 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-4.7%
ultragenyx pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
06:20 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Apr 01 Filed by: Horn Howard
Low
Report
Form 4 Ultragenyx Pharmaceutica For: Apr 01 Filed by: Horn Howard
4/2
08:45 am
rare
Form 8-K Ultragenyx Pharmaceutica For: Apr 02
High
Report
Form 8-K Ultragenyx Pharmaceutica For: Apr 02
4/1
04:13 pm
rare
Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard
Medium
Report
Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard
3/30
08:45 am
rare
Form 8-K Ultragenyx Pharmaceutica For: Mar 30
Medium
Report
Form 8-K Ultragenyx Pharmaceutica For: Mar 30
3/27
04:31 pm
rare
Form ARS Ultragenyx Pharmaceutica For: Dec 31
Low
Report
Form ARS Ultragenyx Pharmaceutica For: Dec 31
3/27
04:31 pm
rare
Form DEFA14A Ultragenyx Pharmaceutica
Low
Report
Form DEFA14A Ultragenyx Pharmaceutica
3/27
04:31 pm
rare
Form DEF 14A Ultragenyx Pharmaceutica For: May 14
Low
Report
Form DEF 14A Ultragenyx Pharmaceutica For: May 14
3/27
01:55 pm
rare
Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
23.4%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
TOP News Decliners
3/16
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
-21.2%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: